<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sonnenblick A</submitter><funding>NCI NIH HHS</funding><pagination>424-432</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6903891</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>52(2)</volume><pubmed_abstract>In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast cancer prognosis, we evaluated the phosphorylated STAT3 (p-STAT3) status and investigated its effect on the outcome in a pooled analysis and in a large prospective adjuvant trial. By using the TCGA repository, we developed gene signatures that reflected the level of p-STAT3. Using pooled analysis of the expression data from luminal breast cancer patients, we assessed the effects of the p-STAT3 expression signature on prognosis. We further validated the p-STAT3 prognostic effect using immunohistochemistry (IHC) and immunofluorescence staining of p-STAT3 tissue microarrays from a large randomised prospective trial. Our analysis demonst</pubmed_abstract><journal>International journal of oncology</journal><pubmed_title>p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.</pubmed_title><pmcid>PMC6903891</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><pubmed_authors>Viale G</pubmed_authors><pubmed_authors>De Azambuja E</pubmed_authors><pubmed_authors>Peretz T</pubmed_authors><pubmed_authors>Crown JPA</pubmed_authors><pubmed_authors>Daly L</pubmed_authors><pubmed_authors>Francis PA</pubmed_authors><pubmed_authors>Sotiriou C</pubmed_authors><pubmed_authors>Javdan B</pubmed_authors><pubmed_authors>Zahavi T</pubmed_authors><pubmed_authors>Di Leo A</pubmed_authors><pubmed_authors>Fujisawa S</pubmed_authors><pubmed_authors>Lieveke A</pubmed_authors><pubmed_authors>Piccart MJ</pubmed_authors><pubmed_authors>Salmon A</pubmed_authors><pubmed_authors>Rouas G</pubmed_authors><pubmed_authors>Sonnenblick A</pubmed_authors><pubmed_authors>Salgado R</pubmed_authors><pubmed_authors>Brohee S</pubmed_authors><pubmed_authors>Bromberg JF</pubmed_authors><pubmed_authors>Van den Eynden G</pubmed_authors></additional><is_claimable>false</is_claimable><name>p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.</name><description>In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast cancer prognosis, we evaluated the phosphorylated STAT3 (p-STAT3) status and investigated its effect on the outcome in a pooled analysis and in a large prospective adjuvant trial. By using the TCGA repository, we developed gene signatures that reflected the level of p-STAT3. Using pooled analysis of the expression data from luminal breast cancer patients, we assessed the effects of the p-STAT3 expression signature on prognosis. We further validated the p-STAT3 prognostic effect using immunohistochemistry (IHC) and immunofluorescence staining of p-STAT3 tissue microarrays from a large randomised prospective trial. Our analysis demonst</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Feb</publication><modification>2025-04-19T19:30:01.237Z</modification><creation>2020-05-21T22:32:03Z</creation></dates><accession>S-EPMC6903891</accession><cross_references><pubmed>29207087</pubmed><doi>10.3892/ijo.2017.4212</doi></cross_references></HashMap>